Resverlogix Corp

(RVXCF)

By |

Profile

Resverlogix Corp is a clinical stage biotechnology company. It is engaged in developing RVX-208, a molecule selective inhibit BET domain inhibitor for the treatment of patients with cardiovascular, diabetes mellitus, Alzheimer's & chronic kidney disease.

Contact Information

Website: www.resverlogix.com
Email: sarah@resverlogix.com
Main Phone: +1 403 254-9252
Address: 4820 Richard Road SW
Address 2: Suite 300
State: AB
City / Town: Calgary
Country: CAN
Postal Code: T3E 6L1

Issuer Information

Exchange: OTO
CEO: Donald McCaffrey
Employees: 28
NAICS: Biological Product (except Diagnostic) Manufacturing (325414)
$ 1.81 $ 0.07 (4.02%)
Last Price 1.81 Change $ 0.07 Change % 4.02 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open 1.77 High 1.81 Low 1.77 Prev Close 1.74
Last Trade Volume 4,975 52 Wk Hi 2.08 52 Wk Low 0.84
Market Cap 320.7 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 177,185,992.00 EPS (TTM) N/A PE Ratio N/A Exchange OTCPK